{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:49:56Z","timestamp":1793303396631,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41388-019-0695-8","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T17:03:58Z","timestamp":1548695038000},"page":"3886-3902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Lysosomal trapping of palbociclib and its functional implications"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-9326","authenticated-orcid":false,"given":"Susana","family":"Llanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Megias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Hern\u00e1ndez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-8465","authenticated-orcid":false,"given":"Miguel","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pietrocola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-9312","authenticated-orcid":false,"given":"Manuel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760\u20136.","journal-title":"Clin Cancer Res"},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1871520615666151019092919","volume":"17","author":"F Chen","year":"2017","unstructured":"Chen F, Zhang J, Xu W, Zhang Y. Progress of CDK4\/6 inhibitor palbociclib in the treatment of cancer. Anticancer Agents Med Chem. 2017;17:1\u20139.","journal-title":"Anticancer Agents Med Chem"},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.4161\/cc.26130","volume":"12","author":"OV Leontieva","year":"2013","unstructured":"Leontieva OV, Blagosklonny MV. CDK4\/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle. 2013;12:3063\u20139.","journal-title":"Cell Cycle"},{"key":"695_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.yexcr.2017.09.031","volume":"360","author":"CA Valenzuela","year":"2017","unstructured":"Valenzuela CA, Vargas L, Martinez V, Bravo S, Brown NE. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res. 2017;360:390\u20136.","journal-title":"Exp Cell Res"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/bph.13836","volume":"174","author":"L Chen","year":"2017","unstructured":"Chen L, Pan J. Dual cyclin-dependent kinase 4\/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol. 2017;174:2427\u201343.","journal-title":"Br J Pharmacol"},{"key":"695_CR6","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","volume":"21","author":"T VanArsdale","year":"2015","unstructured":"VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res. 2015;21:2905\u201310.","journal-title":"Clin Cancer Res"},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0092-8674(03)00401-X","volume":"113","author":"M Narita","year":"2003","unstructured":"Narita M, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703\u201316.","journal-title":"Cell"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence. Trends Cell Biol. 2018;28:436\u2013453.","journal-title":"Trends Cell Biol"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature22797","volume":"546","author":"H Wang","year":"2017","unstructured":"Wang H, et al. The metabolic function of cyclin D3\u2013CDK6 kinase in cancer cell survival. Nature. 2017;546:426\u201330.","journal-title":"Nature"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135.","journal-title":"Nature"},{"key":"695_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798359","volume":"37","author":"TP Miettinen","year":"2018","unstructured":"Miettinen TP. et al. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4\/6 inhibitor palbociclib. EMBO J. 2018;37:e98359","journal-title":"EMBO J"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrm3823","volume":"15","author":"D Mu\u00f1oz-Esp\u00edn","year":"2014","unstructured":"Mu\u00f1oz-Esp\u00edn D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15:482\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tcb.2011.11.006","volume":"22","author":"JC Acosta","year":"2012","unstructured":"Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012;22:211\u20139.","journal-title":"Trends Cell Biol"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"695_CR15","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1242\/jcs.113.20.3613","volume":"113","author":"DJ Kurz","year":"2000","unstructured":"Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113:3613\u201322.","journal-title":"J Cell Sci"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","volume":"92","author":"GP Dimri","year":"1995","unstructured":"Dimri GP, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995;92:9363\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5603\/FHC.2012.0031","volume":"50","author":"M Kna\u015b","year":"2012","unstructured":"Kna\u015b M, et al. The profile of lysosomal exoglycosidases in replicative and stress-induced senescence in early passage human fibroblasts. Folia Histochem Cytobiol. 2012;50:220\u20137.","journal-title":"Folia Histochem Cytobiol"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.molmed.2010.03.003","volume":"16","author":"A Freund","year":"2010","unstructured":"Freund A, Orjalo AV, Desprez P-Y, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. 2010;16:238\u201346.","journal-title":"Trends Mol Med"},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"23238","DOI":"10.18632\/oncotarget.4836","volume":"6","author":"OV Leontieva","year":"2015","unstructured":"Leontieva OV, Demidenko ZN, Blagosklonny MV. Dual mTORC1\/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget. 2015;6:23238\u201348.","journal-title":"Oncotarget"},{"key":"695_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","volume":"17","author":"RM Laberge","year":"2015","unstructured":"Laberge R-M, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049\u201361.","journal-title":"Nat Cell Biol"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/ncb3225","volume":"17","author":"N Herranz","year":"2015","unstructured":"Herranz N, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol. 2015;17:1205\u201317.","journal-title":"Nat Cell Biol"},{"key":"695_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1124\/dmd.112.050054","volume":"41","author":"F Kazmi","year":"2013","unstructured":"Kazmi F, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41:897\u2013905.","journal-title":"Drug Metab Dispos"},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.4155\/bio.09.128","volume":"1","author":"SDB Goldman","year":"2009","unstructured":"Goldman SDB, Funk RS, Rajewski RA, Krise JP. Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis. 2009;1:1445\u201359.","journal-title":"Bioanalysis"},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.phrs.2017.02.013","volume":"119","author":"RR Massaro","year":"2017","unstructured":"Massaro RR, et al. Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. Pharmacol Res. 2017;119:242\u201350.","journal-title":"Pharmacol Res"},{"key":"695_CR25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/onc.2011.277","volume":"31","author":"M Verhaegen","year":"2012","unstructured":"Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene. 2012;31:828\u201341.","journal-title":"Oncogene"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","volume":"20","author":"L Anders","year":"2011","unstructured":"Anders L, et al. A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20:620\u201334.","journal-title":"Cancer Cell"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cyto.a.22495","volume":"85","author":"A Pierzy\u0144ska-Mach","year":"2014","unstructured":"Pierzy\u0144ska-Mach A, Janowski PA, Dobrucki JW. Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long-term tracking of acidic vesicles. Cytometry A. 2014;85:729\u201337.","journal-title":"Cytometry A"},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0076-6879(08)03612-4","volume":"452","author":"G Bj\u00f8rk\u00f8y","year":"2009","unstructured":"Bj\u00f8rk\u00f8y G, Lamark T, Pankiv S, \u00d8vervatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62\/SQSTM1. Methods Enzymol.2009;452:181\u201397. https:\/\/doi.org\/10.1016\/S0076-6879(08)03612-4 .","journal-title":"Methods Enzymol."},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.92.22.10436","volume":"92","author":"W Li","year":"1995","unstructured":"Li W, et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA. 1995;92:10436\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"695_CR30","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.1218351","volume":"336","author":"JE Purvis","year":"2012","unstructured":"Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science. 2012;336:1440\u20134.","journal-title":"Science"},{"key":"695_CR31","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1128\/MCB.22.10.3497-3508.2002","volume":"22","author":"G Ferbeyre","year":"2002","unstructured":"Ferbeyre G, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol. 2002;22:3497\u2013508.","journal-title":"Mol Cell Biol"},{"key":"695_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.","journal-title":"Breast Cancer Res"},{"key":"695_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078641","volume":"8","author":"TJW Robinson","year":"2013","unstructured":"Robinson TJW, et al. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE. 2013;8:e78641.","journal-title":"PLoS ONE"},{"key":"695_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/1744666X.2016.1212659","volume":"13","author":"CC Mok","year":"2017","unstructured":"Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13:35\u201341.","journal-title":"Expert Rev Clin Immunol"},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ejpb.2006.06.005","volume":"64","author":"JJ Palmgr\u00e9n","year":"2006","unstructured":"Palmgr\u00e9n JJ, M\u00f6nkk\u00f6nen J, Korjamo T, Hassinen A, Auriola S. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm. 2006;64:369\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1124\/jpet.109.160226","volume":"333","author":"RA Ndolo","year":"2010","unstructured":"Ndolo RA, Forrest ML, Krise JP. The role of lysosomes in limiting drug toxicity in mice. J Pharmacol Exp Ther. 2010;333:120\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23\u201333.","journal-title":"Drug Resist Updat"},{"key":"695_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0773.1997.tb00285.x","volume":"80","author":"WA Daniel","year":"1997","unstructured":"Daniel WA, W\u00f3jcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol. 1997;80:62\u20138.","journal-title":"Pharmacol Toxicol"},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0278-5846(02)00317-2","volume":"27","author":"WA Daniel","year":"2003","unstructured":"Daniel WA. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:65\u201373.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"695_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0924-977X(99)00034-6","volume":"9","author":"WA Daniel","year":"1999","unstructured":"Daniel WA, W\u00f3jcikowski J. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur Neuropsychopharmacol. 1999;9:483\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"key":"695_CR41","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1124\/dmd.109.027888","volume":"37","author":"T Hay","year":"2009","unstructured":"Hay T, Jones R, Beaumont K, Kemp M. Modulation of the partition coefficient between octanol and buffer at pH 7.4 and pKa to achieve the optimum balance of blood clearance and volume of distribution for a series of tetrahydropyran histamine type 3 receptor antagonists. Drug Metab Dispos. 2009;37:1864\u201370.","journal-title":"Drug Metab Dispos"},{"key":"695_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/jps.20530","volume":"95","author":"N Murayama","year":"2006","unstructured":"Murayama N, Nakaoka M, Sudo K. Contribution of lysosomes to concentrative uptake of DX-9065a into rat liver. J Pharm Sci. 2006;95:1763\u201370.","journal-title":"J Pharm Sci"},{"issue":"6","key":"695_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/bod.2510090602","volume":"9","author":"Anna C. Macintyre","year":"1988","unstructured":"MacIntyre AC, Cutler DJ. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos. 1988;9:513\u201326.","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"695_CR44","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1517\/17425255.2012.691165","volume":"8","author":"R Log.an","year":"2012","unstructured":"Log.an R, Funk RS, Axcell E, Krise JP. Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opin Drug Metab Toxicol. 2012;8:943\u201358.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"695_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan S, et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017;8:15916.","journal-title":"Nat Commun"},{"key":"695_CR46","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S","volume":"67","author":"R Gr\u00e9nman","year":"1991","unstructured":"Gr\u00e9nman R, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer. 1991;67:2741\u20137.","journal-title":"Cancer"},{"key":"695_CR47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/archotol.1994.01880310054010","volume":"120","author":"K Pekkola-Heino","year":"1994","unstructured":"Pekkola-Heino K, Joensuu H, Klemi P, Grenman R. Relation of DNA ploidy and proliferation rate to radiation sensitivity in squamous carcinoma cell lines. Arch Otolaryngol Head Neck Surg. 1994;120:750\u20134.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/BF01218360","volume":"121","author":"K Pekkola-Heino","year":"1995","unstructured":"Pekkola-Heino K, Jaakkola M, Kulmala J, Gr\u00e9nman R. Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol. 1995;121:452\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"695_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2184.1996.01009.x","volume":"29","author":"K Servomaa","year":"1996","unstructured":"Servomaa K, Kiuru A, Gr\u00e9nman R, Pekkola-Heino K, Pulkkinen JO, Ryt\u00f6maa T. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif. 1996;29:219\u201330.","journal-title":"Cell Prolif"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0695-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0695-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0695-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:15:15Z","timestamp":1684617315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-0695-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":49,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-0695-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"31 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The laboratory of M.S. has had a research contract with Pfizer, Inc. on research not mentioned in this work. M.S. is founder and share-holder of Senolytic Therapeutics, Inc. (USA) and Senolytic Therapeutics, S.L. (Spain). The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}